Anti-Zika Virus (ZIKV) E Protein [Clone ZV67] — Purified in vivo GOLD™ Functional Grade
Anti-Zika Virus (ZIKV) E Protein [Clone ZV67] — Purified in vivo GOLD™ Functional Grade
Product No.: Z200
Clone ZV67 Target ZIKV E (Envelope) Formats AvailableView All Product Type Hybridoma Monoclonal Antibody Alternate Names ZIKV E, Envelope protein Isotype Mouse IgG2c κ Applications ELISA , in vivo , N , WB |
Antibody DetailsProduct DetailsReactive Species Mouse Host Species Mouse Recommended Dilution Buffer Immunogen Injection of a Mouse with ZIKV MR-766, ZIKV H/PF/2013, and ZIKV DIII. 1 Product Concentration ≥ 5.0 mg/ml Endotoxin Level <1.0 EU/µg as determined by the LAL method Purity ≥95% monomer by analytical SEC ⋅ >95% by SDS Page Formulation This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration. Product Preparation Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates. Storage and Handling This antibody may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles. Country of Origin USA Shipping Next Day 2-8°C Additional Applications Reported In Literature ? N ELISA WB Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity Clone ZV-67 binds to the Zika virus envelope (E) protein at domain III (DIII, LR). 1 Background Zika virus (ZIKV) infection during pregnancy is a global public health problem 1, linked causally to severe fetal abnormalities 2. Prophylactic antibodies may prove useful in treating pregnant patients or for designing epitope-specific vaccines 1. The mouse monoclonal antibody (MAb) ZV-67 specifically targets ZIKV and neutralizes infection of the American, Asian, and African strains to varying degrees 1.
ZIKV is a mosquito-transmitted flavivirus that encodes a single polyprotein with an ~11 kb positive-sense RNA open reading frame 1. The polyprotein is cleaved into seven non-structural (NS) proteins and three structural proteins (capsid (C), pre-membrane (prM), and envelope (E)). C forms a nucleocapsid. prM complexes with E to facilitate folding and prevent premature fusion to host membranes. E is responsible for viral assembly, attachment, entry, and fusion 1,3 and is a major target of neutralizing antibody research 3. Mature ZIKV virions incorporate 180 copies each of the E and M proteins 4,5. E is divided into three domains, DI, DII, and DIII 3. DI is a central β-barrel, DII is an extended dimerization domain, and DIII is an immunoglobulin-like segment. The lateral ridge of DIII is targeted by the ZV-67 MAb 1. ZV-67 was generated by priming a lethal mouse model with ZIKV (MR-766 and H/PF/2013) and DIII domain. ZV-67 is of the IgG2c isotype and has been shown to neutralize the MR-766, Uganda 1947, Dakar 41519, and Senegal 1982 African strains as well as the American Paraiba 2015, Brazil strain. It has no cross-reactivity with Japanese Encephalitis or Dengue. Analysis of antibody contact residues by X-ray crystallography shows that ZV-67 binds to the heavy chain complementarity determining region of DIII. A total of 21 residues are contacted by ZV-67, representing four discrete secondary structure elements of the A-strand, B-C, D-E, and F-G loops. Antigen Distribution The Envelope (E) protein expressed on the Zika Virus PubMed Research Area Category B Pathogens . Infectious Disease . Viral . Zika . IVD Raw Material Leinco Antibody AdvisorPowered by AI: AI is experimental and still learning how to provide the best assistance. It may occasionally generate incorrect or incomplete responses. Please do not rely solely on its recommendations when making purchasing decisions or designing experiments. Clone ZV-67 is primarily used in mouse studies for passive immunotherapy to evaluate protective efficacy against Zika virus (ZIKV) infection. This monoclonal antibody, which targets the lateral ridge of domain III (DIII-LR) of the Zika virus envelope protein, has demonstrated significant therapeutic potential in several experimental contexts. Lethal Challenge Protection StudiesThe most common application involves passive transfer experiments where ZV-67 is administered to mice before lethal ZIKV challenge. In these studies, 4-5 week-old C57BL/6 mice receive the antibody (typically 250 μg) along with anti-Ifnar antibody one day before infection with pathogenic ZIKV strains. This approach has consistently demonstrated that ZV-67 provides complete clinical protection against lethal infection, reducing viremia and preventing the weight loss and mortality observed in control animals. Heterologous Strain ProtectionZV-67 has proven effective against multiple ZIKV strains in vivo, including the highly pathogenic African strain Dakar 41519. The antibody's broad neutralizing capacity makes it valuable for testing cross-strain protection, particularly important given ZIKV's genetic diversity across different geographic lineages. Vaccine and Immunogen DevelopmentZV-67 serves as a critical tool in vaccine research, being used as a positive selection target in phage display experiments to identify and validate resurfaced ZIKV envelope domain III immunogens. Researchers use ZV-67 binding as a benchmark to ensure that modified antigens retain immunologically relevant epitopes while potentially reducing off-target responses. The antibody's consistent protective activity in stringent mouse models deficient in type I interferon signaling has established it as a standard reference for evaluating novel therapeutic antibodies and vaccine candidates against ZIKV infection. Some of the most commonly used antibodies or proteins studied alongside ZV67 in the literature are other mouse monoclonal antibodies targeting Zika virus Domain III (DIII), particularly ZV-2, ZV-48, ZV-54, and ZV-64. These antibodies are frequently used in panels for structural, functional, competition, and neutralization studies. Key details regarding commonly co-used antibodies and proteins:
Most literature involving ZV67 engages the above panel of mouse mAbs to elucidate precise epitope mapping, antibody competition, and functional importance, as their epitopes are close but non-overlapping or, in some cases, competitive within ZIKV DIII. Control antibodies such as 4G2 and CHK-166, as well as engineered DIII proteins, also frequently appear in studies with ZV67 for experimental validation or as assay standards. Key findings from scientific literature on clone ZV67 consistently highlight its importance as a potent, broadly neutralizing, and structurally well-characterized monoclonal antibody targeting Zika virus (ZIKV):
In summary, ZV-67 is a lead candidate for ZIKV therapy, a critical reagent for epitope mapping and vaccine design, and a model for understanding flavivirus neutralization. Studies involving ZV-67 are foundational for both basic research and translational applications targeting Zika virus. The dosing regimens of clone ZV67, a monoclonal antibody targeting the Zika virus, vary across different mouse models primarily due to factors such as mouse strain, immune competence, adjuvant selection, and dose schedule. These variations are tailored to maximize immunogenicity and protection in each model. For instance, different mouse strains (e.g., BALB/c, C57BL/6) may require different dosing strategies to achieve optimal immune responses. Additionally, the choice of adjuvant can affect the efficacy of the antibody in inducing protection against Zika virus infection. In general, the dosing regimens are optimized to ensure that the antibody effectively neutralizes the virus and provides protection against lethal challenges. This involves adjusting the dose amount and frequency based on the specific requirements of each mouse model. However, specific details about the exact dosing schedules (e.g., amount per dose, frequency of administration) for ZV67 in various mouse models are not explicitly outlined in the available information. Key Variables:
These factors are crucial in designing effective dosing regimens for ZV67 in mouse models to ensure optimal protection against Zika virus infection. References & Citations1. Zhao H, Fernandez E, Dowd KA. et al. (2016). Cell. 166(4):1016-1027. 2. Brasil P, Pereira Jr JP, Moreira ME. et al. (2016). N Engl J Med. 375(24):2321-2334. 3. Dai L, Song J, Lu X. et al. (2016). 19(5):696-704. 4. Kostyuchenko VA, Lim EX, Zhang S. et al. (2016). Nature. 533(7603):425-428. 5. Sirohi D, Chen Z, Sun L. et al. (2016). Science. 352(6284):467-470. 6. Yi G, Xu X, Abraham S. et al. (2017). EBioMedicine. 25:87-94. Technical Protocols  N  Certificate of Analysis |
Formats Available
Prod No. | Description |
|---|---|
Z200 |
Products are for research use only. Not for use in diagnostic or therapeutic procedures.
